Nuveen
CSBR icon

Nuveen’s Champions Oncology CSBR Stock Holding History

Nuveen’s Portfolio CSBR Stock Details CSBR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$484 Buy
+101
New +$539 ﹤0.01% 4986
2021
Q2 		– Sell
-12,642
Closed -$143K – 3401
2021
Q1 		$143K Hold
12,642
– – ﹤0.01% 3262
2020
Q4 		$136K Hold
12,642
– – ﹤0.01% 3228
2020
Q3 		$117K Hold
12,642
– – ﹤0.01% 3209
2020
Q2 		$121K Buy
+12,642
New +$108K ﹤0.01% 3150

Other funds holding CSBR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $106B AUM 21.33% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Mesirow Financial Investment Management
Mesirow Financial Investment Management Chicago, Illinois $6.47B AUM 15.41% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $45.2B AUM 20.72% 1-Year Est. Return
Cassaday & Co Wealth Management
Cassaday & Co Wealth Management Mclean, Virginia $5.65B AUM 14.23% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Nuveen's CSBR Position: Q3 2026 in Review

Nuveen opened a new position in Champions Oncology (CSBR) in Q3 2026: 101 shares worth $484. The stake represents ﹤0.01% of the portfolio and ranks #4986 among its holdings. This is a return to the name: Nuveen previously reported a position in CSBR as recently as Q1 2021.

Nuveen first reported a position in CSBR in Q2 2020 and has held it in 5 quarters since. The position peaked at $143K in Q1 2021. 11 funds tracked by Wall St. Rank hold CSBR as of Q3 2026.

  • Nuveen held 101 shares of Champions Oncology worth $484 as of Q3 2026.
  • Champions Oncology was a new Nuveen position in Q3 2026.
  • Champions Oncology made up ﹤0.01% of Nuveen's portfolio in Q3 2026, its #4986 holding.
  • Nuveen first reported a position in Champions Oncology in Q2 2020 and has held it in 5 quarters since.
  • Nuveen's Champions Oncology position peaked at $143K in Q1 2021.
  • 11 funds tracked by Wall St. Rank held Champions Oncology as of Q3 2026.

Based on Nuveen's 13F filing for Q3 2026, filed 10 Nov 2026.